Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 22;17(1):202.
doi: 10.1186/s12883-017-0983-2.

The humanistic burden of Pompe disease: are there still unmet needs? A systematic review

Affiliations

The humanistic burden of Pompe disease: are there still unmet needs? A systematic review

Benedikt Schoser et al. BMC Neurol. .

Abstract

Background: Humanistic burden considers the impact of an illness on a patient's health-related quality of life (HRQoL), activities of daily living (ADL), caregiver health, and caregiver QoL. Humanistic burden also considers treatment satisfaction and adherence to treatment regimens. Pompe disease is an autosomal recessive, progressive, multisystemic neuromuscular disease. Approval of enzyme-replacement therapy (ERT) markedly improved prognosis for patients, but considerable morbidity and a substantial humanistic burden remain. This article characterizes the humanistic burden of Pompe disease through a systematic literature review.

Methods: A systematic search of MEDLINE® and Embase® with back-referencing and supplementary literature searches was performed to retrieve data from interventional and non-interventional studies on the humanistic burden of Pompe disease. Publications were screened according to predefined criteria, extracted, and assessed for quality. Extracted data were narratively synthesized.

Results: No publications on the humanistic burden of infantile-onset Pompe disease (IOPD) were identified. As such, of 17 publications included here, all are in patients with late-onset Pompe disease (LOPD). Thirteen publications were initiated after approval of ERT, two were initiated before, and two overlapped the approval of ERT. The review shows that LOPD patients have a significantly lower HRQoL than the general population, even if treated with ERT. On transitioning to ERT, treatment was associated with improvement in the physical component score of the SF-36 and fatigue, although the SF-36 mental component score remained stable. Physical HRQoL remained below population norms after 4 years of ERT. Significantly more ERT-treated patients reported pain than controls, and bodily pain worsened in later years following ERT initiation. Treatment-naïve LOPD patients had significantly poorer ADL functioning compared with the general population, although ERT stabilized deteriorating functioning impairment. ERT studies showed caregivers provide 17.7 h/week informal care on average. Fifty percent, 40% and <20% of caregivers reported mental health, physical health, and financial/relational problems, respectively. In ERT-naïve patients, wheelchair use and home ventilatory support was associated with lower physical HRQoL and ADL functioning. In ERT-treated patients, key factors predicting worse HRQoL and ADL functioning were higher respiratory distress, poorer sleep quality, greater pain, and more fatigue.

Conclusions: Pompe disease has a substantial humanistic burden, with strong inter-relationships among and between humanistic burden parameters and clinical progression.

Keywords: Caregiver burden; Daily living; Humanistic burden; Pompe; Quality of life.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Competing interests

BS is member of the Audentes Therapeutics Board of Scientific and Clinical Advisors. BS has received unrestricted research support, honoraria, and travel funding from Sanofi Genzyme during the past 5 years. BS received honoraria and travel funding as member of the Global Advisory Boards from Biomarin Pharmaceutical, Amicus Therapeutics, and Audentes Therapeutics. DB is a member of the Audentes Therapeutics Board of Scientific and Clinical Advisors. DD is member of the Audentes Therapeutics Board of Scientific and Clinical Advisors. DD has received consulting fees and related expenses from Biomarin, Demeter Therapeutics, Complete Genomics and Illumina during the past 5 years. DD received, through his institution, restricted research grants and related travel funding from Biomarin, Genzyme Sanofi, Hyperion, Alexion and Demeter Therapeutics. EJ and SP are employed by and own stock in Audentes Therapeutics.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flowchart of screening and identification process
Fig. 2
Fig. 2
Inter-relationships between clinical, humanistic and economic burden parameters in LOPD patients receiving ERT

Similar articles

Cited by

References

    1. Ebbink BJ, Aarsen FK, van Gelder CM, van den Hout JM, Weisglas-Kuperus N, Jaeken J, et al. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology. 2012;78:1512–1518. doi: 10.1212/WNL.0b013e3182553c11. - DOI - PubMed
    1. Ebbink BJ, Aarsen FK, van Gelder CM, van den Hout JMP, Weisglas-Kuperus N, Jaeken J, et al. Cognitive outcome of classic infantile Pompe patients receiving enzyme therapy. BMC Musculoskelet Disord. 2013;14(Suppl 2):14. - PubMed
    1. van Gelder CM, van Capelle CI, Ebbink BJ, Moor-van Nugteren I, van den Hout JM, Hakkesteegt MM, et al. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis. 2012;35:505–511. doi: 10.1007/s10545-011-9404-7. - DOI - PMC - PubMed
    1. Bhengu L, Davidson A, du Toit P, Els C, Gerntholzt T, Govendrageloo K, et al. Diagnosis and management of Pompe disease. S Afr Med. 2014;104:273–274. doi: 10.7196/SAMJ.7386. - DOI - PubMed
    1. Chien Y-H, Hwu W-L, Lee N-C. Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol. 2013;54:219–227. doi: 10.1016/j.pedneo.2013.03.009. - DOI - PubMed

Publication types